Companies › Sovargen
1 active drug program in 8 registered trials: 4 Phase 1, 4 Phase 2; Oncology, Other; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Paxalisib (SVG103) PI3-kinase class I inhibitor | PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2 | Phase 1 | Focal Cortical Dysplasia; Primary Central Nervous System Lymphoma; Glioblastoma; CDK Gene Mutation … | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04906096 | Paxalisib (SVG103) | Phase 2 | Primary Central Nervous System Lymphoma | Oncology | Dec 2026 |
| NCT04192981 | Paxalisib (SVG103) | Phase 1 | Brain Metastases | Oncology | Dec 2026 |
| NCT07287202 | Paxalisib (SVG103) | Phase 1 | Focal Cortical Dysplasia | Other | Feb 2027 |
| NCT03970447 | Paxalisib (SVG103) | Phase 2 | Glioblastoma | Oncology | Jun 2028 |
| NCT03994796 | Paxalisib (SVG103) | Phase 2 | CDK Gene Mutation | Oncology | Jun 2028 |
| NCT07391215 | Paxalisib (SVG103) | Phase 1 | Malignant Primary Gliomas | Oncology | Jan 2029 |
| NCT06208657 | Paxalisib (SVG103) | Phase 1 | Childhood Cancer | Oncology | Dec 2030 |
| NCT07447076 | Paxalisib (SVG103) | Phase 2 | Recurrent Atypical Teratoid/Rhabdoid Tumor | Oncology | Dec 2035 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.